ISDA

Deposition Date 2021-04-16

Release Date 2022-07-20

Last Version Date 2023-11-29

Entry Detail

PDB ID:

7EN8

Keywords:

VIRAL PROTEIN

Title:

Crystal structure of SARS-CoV-2 3CLpro in complex with the non-covalent inhibitor WU-04

Biological Source:

Source Organism:

Severe acute respiratory syndrome coronavirus 2 (Taxon ID: 2697049)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.83 Å

R-Value Free:

0.27

R-Value Work:

0.22

R-Value Observed:

0.22

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:3C-like proteinase
Chain IDs:A, B
Chain Length:306
Number of Molecules:2
Biological Source:Severe acute respiratory syndrome coronavirus 2

UniProt ID:P0DTD1 Pfam ID:PF05409

Ligand Molecules

GOL

J7R

Primary Citation

Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro.

Hou, N, Shuai, L, Zhang, L, Xie, X, Tang, K, Zhu, Y, Yu, Y, Zhang, W, Tan, Q, Zhong, G, Wen, Z, Wang, C, He, X, Huo, H, Gao, H, Xu, Y, Xue, J, Peng, C, Zou, J, Schindewolf, C, Menachery, V, Su, W, Yuan, Y, Shen, Z, Zhang, R, Yuan, S, Yu, H, Shi, P.Y, Bu, Z, Huang, J, Hu, Q.Show

Acs Cent.Sci. 9 217 227 (2023)

PMID: 36844503 DOI: 10.1021/acscentsci.2c01359

Abstact

The 3C-like protease (3CLpro) is an essential enzyme for the replication of SARS-CoV-2 and other coronaviruses and thus is a target for coronavirus drug discovery. Nearly all inhibitors of coronavirus 3CLpro reported so far are covalent inhibitors. Here, we report the development of specific, noncovalent inhibitors of 3CLpro. The most potent one, WU-04, effectively blocks SARS-CoV-2 replications in human cells with EC50 values in the 10-nM range. WU-04 also inhibits the 3CLpro of SARS-CoV and MERS-CoV with high potency, indicating that it is a pan-inhibitor of coronavirus 3CLpro. WU-04 showed anti-SARS-CoV-2 activity similar to that of PF-07321332 (Nirmatrelvir) in K18-hACE2 mice when the same dose was administered orally. Thus, WU-04 is a promising drug candidate for coronavirus treatment.

Legend

Protein

Chemical

Disease

Primary Citation of related structures